GRANITE-1: Second-line everolimus did not extend OS for advanced gastric cancer HemOncToday SAN FRANCISCO — Patients assigned to everolimus monotherapy did not enjoy a survival benefit, according to phase-3 results from the GRANITE-1 trial presented here. Although everolimus (Afinitor, Novartis) extended 6-month PFS, the drug failed to meet ... |
